New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.
NEW YORK, NY -- (Marketwired) -- 10/09/14 -- After careful analysis, Stock Market Media Group (SMMG), a research and content development IR firm, announces that it has initiated coverage on Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with 4 novel drugs currently in its pipeline under development. In a new Report, SMMG examines the company's unique drug development strategy, its pipeline of drugs for the treatment of pain, the multi-billion dollar market in which the biotech's products will compete, and both the impressive management team and Scientific Advisory Board that will lead the firm into the future.
Read the new Report: www.stockmarketmediagroup.com/reports.
Relmada Therapeutics recently became a publicly traded biopharmaceutical firm, and with the move from private to public, the company brings its unique brand of drug development to the investment community. The company has chosen to build a pipeline of drugs that will compete in the largest prescription market in the world - the treatment of pain. Relmada executives say that their portfolio will address an "unmet medical need" in the treatment of pain.
Three of the four novel pain drugs in Relmada's pipeline are being developed through the FDA's 505(b)(2) regulatory approval pathway. It's a process that allows the company to take pain medicines that have already been approved by the FDA and make small modifications to them with the expectation that Relmada can significantly improve efficacy, patient safety and patient convenience.
The strategy will assist Relmada in bringing its "repurposed drugs" to market much faster and at a fraction of the cost of typical drug development. Because the drugs being improved upon have already been approved by the FDA, Relmada will have to pay for fewer studies during development, and with fewer studies to conduct, this strategy is generally faster if done correctly.
Relmada's pain drugs, LevoCap ER, MepiGel and BuTab ER will be developed using the 505(b)(2) strategy, while another, d-methadone, will be developed using the traditional new drug application (NDA) process.
In 2013 alone, 334 million pain prescriptions were written in the U.S., and pain represents the most frequent reason given for physician visits in this country. Relmada has chosen to compete in a market that affects more people in the U.S. than diabetes, heart disease and cancer combined.
Driving the newly public Relmada Therapeutics is its top notch management team and a strong Scientific Advisory Board. Management is headed by Chief Executive Officer, Sergio Traversa, PharmD, MBA, and his more than 25 years of experience in the healthcare sector in both the US and Europe, and its President and Chief Scientific Officer, Eliseo Salinas, MD, MSc, whose impressive track record of developing successful drugs has led to 15 programs obtaining regulatory approval in the U.S. and other major international markets under his guidance.
Read the new Report: www.stockmarketmediagroup.com/reports.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm that offers a platform for corporate stories to unfold in the media with Research Reports, CEO Interviews and Feature Articles. SMMG has been compensated for this Relmada Therapeutics, Inc. report by the company. For more information on Stock Market Media Group visit: www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email contact
Source: Relmada Therapeutics, Inc.
Released October 9, 2014